News

Camrelizumab Plus Apatinib for Platinum-Refractory Nasopharyngeal Carcinoma

03/08/2023

Allison Casey

In a phase 2 trial, camrelizumab plus apatinib showed promising antitumor activity among patients with nasopharyngeal carcinoma who had previously been treated with at least 1 line of systemic therapy.

In a phase 2 trial, camrelizumab...

03/08/2023

Oncology

News

Docetaxel as a Radiosensitizer for Cisplatin-Ineligible Patients With Head and Neck Squamous Cell Carcinoma

02/10/2023

Allison Casey

Docetaxel was found to be safe and effective as a radiosensitizer for cisplatin-eligible patients with head and neck squamous cell carcinoma, according to results from a phase 3 study.

Docetaxel was found to be safe...

02/10/2023

Oncology

News

Nivolumab Plus Ipilimumab Did Not Improve OS for Patients With Squamous Cell Carcinoma of the Head and Neck

01/12/2023

Allison Casey

According to the phase 3 CheckMate 651 trial, nivolumab plus ipilimumab did not improve the overall survival of patients with recurrent or metastatic squamous cell carcinoma of the head and neck, compared to the EXTREME regimen.

According to the phase 3...

01/12/2023

Oncology

News

Pembrolizumab vs Chemotherapy for Platinum-Treated, Recurrent or Metastatic Nasopharyngeal Cancer

01/06/2023

Allison Casey

According to final analysis of the phase 3 KEYNOTE-122 study, pembrolizumab did not demonstrate improved efficacy vs chemotherapy in platinum-pretreated patients with nasopharyngeal cancer.

According to final analysis of...

01/06/2023

Oncology

Jean-Pascal Machiels, MD, Cliniques Universitaires Saint Luc

Videos

Pembrolizumab Added to Chemoradiotherapy May Improve EFS in Head and Neck Squamous Cell Carcinoma

11/15/2022

Jean-Pascal Machiels, MD, discusses results from the phase 3 KEYNOTE-412 trial showing the addition of pembrolizumab to chemoradiotherapy is associated with a favorable trend toward improved EFS for patients with locally advanced head and...

Jean-Pascal Machiels, MD,...

11/15/2022

Oncology

News

Adjuvant Capecitabine After Chemoradiotherapy Improves Failure-Free Survival in Nasopharyngeal Carcinoma

11/09/2022

Allison Casey

When compared to observation, adjuvant capecitabine following concurrent chemoradiotherapy improves failure-free survival in patients with locoregionally advanced nasopharyngeal carcinoma, according to study findings.

When compared to observation,...

11/09/2022

Oncology

News

Low-Dose Nivolumab Added to Metronomic Chemotherapy Improves OS in Advanced Head and Neck Squamous Cell Carcinoma

10/27/2022

Allison Casey

Findings from a phase 3 superiority study show low-dose nivolumab added to metronomic chemotherapy improves OS and is an alternative standard of care for patients with advanced head and neck squamous cell carcinoma.

Findings from a phase 3...

10/27/2022

Oncology

Denis Soulières, Centre Hospitalier de l’Université de Montréal

Videos

Pembrolizumab for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

09/12/2022

Denis Soulières, MD, discusses long-term follow-up data from the phase 3 KEYNOTE-040 and KEYNOTE-048 clinical trials examining pembrolizumab for patients with head and neck squamous cell carcinoma.

Denis Soulières, MD, discusses...

09/12/2022

Oncology

News

Induction Chemotherapy Before Concurrent Chemoradiotherapy Improves OS in Nasopharyngeal Carcinoma

07/29/2022

Allison Casey

According to final results of a phase 3 trial, the addition of gemcitabine and cisplatin induction chemotherapy before concurrent chemoradiotherapy significantly improved OS in patients with nasopharyngeal carcinoma, with no increased risk of...

According to final results of a...

07/29/2022

Oncology

News

Neutrophil-Lymphocyte Ratio Prognosticates Survival in Head and Neck Cancer

06/13/2022

John Otrompke

Study findings suggest high neutrophil-lymphocyte ratio is associated with worse overall survival and cancer-specific survival in patients with nonmetastatic head and neck cancer.

Study findings suggest high...

06/13/2022

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology